The Kids Research Institute Australia logo
Donate

Discover Prevent Cure

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL).

Citation:
Laurent AP, Siret A, Ignacimouttou C, Panchal K, Diop M, ...... Cheung L, Crispino JD, Gaudry M, ...... Kotecha RS, Geoerger B, Ballerini P, .......  Malinge S. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. Clin Cancer Res. 2020;26(13):3307-18.

Keywords:
Lymphoblastic leukemia; B-cell acute lymphoblastic leukemia; Down Syndrome; preclinical cohort

Abstract:
Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL).